Clinical Trial Details

USOR 17038

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Lung Cancer
Study Type: Interventional
Phase: Phase I
Study Start Date: 09/25/17
Study Completion Date: 03/2020

A Study of MGCD516 in Patients With Advanced Cancer and Any Loss of function mutation in CBL Genetic Alteration in AXL.

NCT Number

NCT02219711

Principal Investigator(s)

John Wallmark, MD

Sponsor(s)

Mirati Therapeutics Inc.

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female